Human Genome stays at neutral by Merrill

Human Genome Sciences, Inc. was kept at a neutral rating by Merrill Lynch analyst Hari Sambasivam on news that the company reported a substantial sale/leaseback agreement involving a sale of its headquarters and its manufacturing facility for $425 million. The analyst looks for clarity on the development path for Lymphostat-B and Albuferon, with initiation of phase 3 trials expected in the second half of this year and progress on managing the significant burn rate and declining cash balances. Shares of the Rockville, Md., biopharmaceutical company were down $0.16, or 1.46%, at $10.80 on volume of 2,824,879 shares versus the three-month running average of 3,630,990 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.